Primary Retroperitoneal Lymph Node Dissection in Clinical Stage A Non‐seminomatous Germ Cell Testis Cancer Review of the Indiana University Experience 1965–1989

Wiley - Tập 71 Số 3 - Trang 326-335 - 1993
John P. Donohue1, John Thornhill1, Richard S. Foster1, Randall G. Rowland1, Richard Bihrle1
1Department of Urology, Indiana University Medical Centre, Indianapolis, USA

Tóm tắt

Summary— The results of primary retroperitoneal lymph node dissection (RPLND) in 464 patients with clinical stage A non‐seminomatous germ cell (NSGC) testis cancer treated over 25 years (1965–1989) were reviewed. The results were analysed in clinical terms and subdivided into early (1965–1978) and contemporary (1979–1989) groups in order to be comparable with series using radiotherapy or surveillance. Between 1965 and 1978 (86 clinical stage A patients) the overall relapse rate of 15% (n = 13) was similar to that of radiotherapy series but survival (97.7% after RPLND) was superior to that achieved with irradiation (87%). From 1979 to 1989, 378 clinical stage A patients had primary RPLND and 30% of them (n = 112) had cancerous nodes. The relapse rate for pathological stage A (n = 266) was 12% and 2 patients died. The relapse rate in pathological stage B patients without adjuvant chemotherapy was 34%. No relapse was seen among 48 pathological stage B patients who received post‐operative adjuvant chemotherapy. The death rate was 0.8% among 378 clinical stage A RPLND patients.While not statistically significantly different from death rates reported in current surveillance series, these consistent results spanning 2 eras (before and after cisplatin) over 25 years suggest a sound basis for the surgical approach. The anatomical and medical principles in oncology, which have supported this approach, still remain cogent today. Now that nerve‐sparing techniques have been developed, the only long‐term morbidity of RPLND (anejaculation) has been avoided. It would seem appropriate to include nerve‐sparing RPLND techniques in the management of clinical stage A disease.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(51)93202-3

10.1016/S0022-5347(17)54590-5

Donohue J. P., 1984, Metastatic pathways of nonseminomatous germ cell tumors, Semin. Urol., 2, 217

10.1002/1097-0142(19870801)60:3 <490::AID-CNCR2820601510>3.0.CO;2-1

10.1016/S0022-5347(17)39434-X

Donohue J. P., 1990, The evolution of surgical templates and nerve‐sparing techniques in retroperitoneal lymphadenectomy for low stage testis cancer, J. Urol., 143, 395A

10.1200/JCO.1989.7.3.387

10.1016/S0140-6736(87)90889-0

Hinman F., 1919, The radical operation for teratoma testis, Surg. Gynecol. Obstet., 28, 495

10.1177/014107688107400610

Liedke S., 1990, Wait and see in NSGCT clinical stage I: a critical assessment after eight years, J. Urol., 143, 397A

10.1111/j.1464-410X.1983.tb03421.x

Peckham M. J., 1982, Recent Advances in Clinical Oncology., 107

10.1016/S0140-6736(82)90710-3

10.1177/003591577406700443

10.1200/JCO.1990.8.1.16

10.1136/bmj.287.6404.1503

10.1111/j.1464-410X.1988.tb05095.x

10.1200/JCO.1991.9.9.1543

10.1016/S0022-5347(17)54015-X

10.1111/j.1464-410X.1989.tb06018.x

Sogani P. C., 1988, Surveillance alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis (NSGCT), Semin. Urol., 6, 53

10.1200/JCO.1988.6.10.1597

10.1111/j.1464-410X.1976.tb06654.x

10.1056/NEJM198712033172303

Thông tin
Thông tin xuất bản

Wiley

Tập 71 Số 3

326-335

Thông tin tác giả